- The consistent use of Mexidol® from a solution to tablets, which is actualized in specialized large randomized clinical studies (RCTs) 5, 7 allows us to recommend the use of this scheme for the complete disclosure of the therapeutic potential of the drug Mexidol®.
How to apply Mexidol®
Therapy schemes
Mexidol® is effectively used in both adults and children from 6 years old. In the drop -down list below
you can choose the readings, and you will be shown the recommended scheme of therapy.
Indications for use 1
The presence of injection and tablet dosage forms of Mexidol® allows for consistent therapy, and a wide range of doses - to apply an individual approach to each patient, revealing the maximum therapeutic potential of the drug.
Recommended
standard for therapy 5, 7
standard for therapy 5, 7
- Children's therapy
Forms of release
2 ml No. 10
5 ml No. 5
10 ml No. 5
Mexidol® solution for iv
and iv in introduction 50 mg/ml
and iv in introduction 50 mg/ml
1 milliliter 50 mg of active substance
Indications for use 1
- acute cerebrovascular disorders;
- traumatic brain injury, consequences of traumatic brain injuries;
- discirculatory encephalopathy;
- chronic brain ischemia;
- vegetative dystonia syndrome;
- light (moderate) cognitive disorders;
- alarming disorders in neurotic and neurosis -like conditions;
- acute myocardial infarction (from the first day) as part of complex therapy;
- primary open -angle glaucoma of various stages, as part of complex therapy;
- relief of withdrawal syndrome in alcoholism with a predominance of neurosis-like and vegetative-vascular disorders;
- acute intoxication with antipsychotic agents;
- Acute purulent-inflammatory processes of the abdominal cavity (acute necrotic pancreatitis, peritonitis) as part of complex therapy.
№30
№50
Mexidol® tablets covered with a film shell 125 mg
in 1 tablet 125 mg of active substance
allowed for children from 6 years old
Indications for use 2
- The consequences of acute cerebrovascular accident, including after transient ischemic attacks, in the subcompensation phase as preventive courses;
- light cranial injury, consequences of traumatic brain injuries;
- encephalopathy of various genes (discirculatory, dysmetabolic, post -traumatic, mixed);
- vegetative dystonia syndrome;
- light cognitive disorders of atherosclerotic genesis;
- alarming disorders in neurotic and neurosis -like conditions;
- coronary heart disease in complex therapy;
- the relief of withdrawal syndrome in alcoholism with a predominance of neurosis-like and vegetative-vascular disorders, postbustified disorders;
- condition after acute intoxication with antipsychotic agents;
- asthenic conditions, as well as for the prevention of the development of somatic diseases under the influence of extreme factors and loads;
- impact of extreme (stressor) factors;
- Syndrome of attention deficiency with hyperactivity (ADHD) in children, including hyperactivity, impaired attention, impulsiveness.
№40
Mexidol® Fort 250 tablets covered with
250 mg
250 mg
in 1 tablet 250 mg of active substance
Indications for use 3
- consequences of acute cerebrovascular accident, including after transient ischemic attacks, in the subcompensation phase as preventive courses;
- light cranial injury, consequences of traumatic brain injuries;
- encephalopathy of various genes (discirculatory, dysmetabolic, post -traumatic, mixed);
- vegetative dystonia syndrome;
- light cognitive disorders of atherosclerotic genesis;
- alarming disorders in neurotic and neurosis -like conditions;
- coronary heart disease in complex therapy;
- the relief of withdrawal syndrome in alcoholism with a predominance of neurosis-like and vegetative-vascular disorders, postbustified disorders;
- condition after acute intoxication with antipsychotic agents;
- asthenic conditions, as well as for the prevention of the development of somatic diseases under the influence of extreme factors and loads;
- The impact of extreme (stressor) factors.
Mexidol® is available in the following pharmacies:
Where to buy
You can order right now. Click on the logo of the Internet pharmacy, and you will be redirected to the order page*
*When ordering, a request to take into account that the product is a drug for prescription.
Where to buy
List of literature
- General characteristics of the drug Mexidol® 50 mg/ml, a solution for intravenous and intramuscular administration of LP-№ 000107 RG-RUR dated 12.12.2023
- General characteristics of the drug Mexidol® 125 mg, tablets coated with the film shell of LP-№ 000086 RG-RUR dated 08.02.2023
- General characteristics of the drug Mexidol® Fort 250, 250 mg, tablets covered with the film shell of lp-№ 000066 RG-RUR dated 12/19/2023
- Zavadenko N. N., Suvorinova N. Yu., Batysheva T. T., Bykova O. V., Platonova A.N., Gainetdinova D. D., Levitina E.V., Machin V.V., Vakula and Vakula and Vakula and . Journal of neurology and psychiatry named after S. S. Korsakova. 2022; 122 (4): 75–86.
- Stakhovskaya L.V., Shamalov N. A. The results of a randomized double-cententer placebo-controlled multicenter-controlled in parallel groups of the efficiency and safety of Mexidol with prolonged sequential therapy in patients in the acute and early recovery periods of the half-step ischemic stroke (Epica) // Journal of Neurology and the Journal of Neurology Psychiatry named after S. S. Korsakova, No. 3, 2017, Issue 2 “Stroke”, pp. 55–65.
- Strelnikova I.A. with co -author. The effectiveness and safety of the drug Mexidol Fort 250 in the framework of prolonged consistent therapy in patients with ischemic stroke in the carotid system // Journal of Neurology and Psychiatry named after S. S. Korsakova. 2020; 120 (3 outp. 2): 54-59.
- Fedin A.I., Zakharov V.V., Tanashyan M. M., Chukanova E.I., Majidova E. N., Shchepanevich L. A., Ostroumova O. D. The results of an international multicenter randomized bouncer-controlled Studies of assessing the effectiveness and safety of consistent therapy of patients with chronic brain ischemia drugs Mexidol and Mexidol Forte 250 (study of Memo). Journal of neurology and psychiatry named after S. S. Korsakova. 2021; 121 (11): 7-16.
- Bogolepova A. N. Features of pharmacotherapy of vascular cognitive disorders in elderly people. Journal of neurology and psychiatry named after S. S. Korsakova. 2023; 123 (9): 15–20.
- Zakharov V.V., Tkacheva O. N., Mkhitaryan E.A., Fedin A. I. The effectiveness of Mexidol in patients of different age groups with chronic brain ischemia and cognitive disorders (the results of the subanalysis of the international multicenth-centered double blind and controlled study Memo). Journal of neurology and psychiatry named after S. S. Korsakova. 2022; 122 (11 outp. 2): 1–8.
- Chukanova E.I., Chukanova A.S. The effectiveness and safety of the drug Mexidol Forte 250 in the framework of consistent therapy in patients with chronic brain ischemia. Journal of neurology and psychiatry named after S. S. Korsakova. 2019; 119 (9): 39-45.
- Abramenko Yu. V. The results of the sequential use of Mexidol and Mexidol Forte 250 in patients with chronic brain ischemia. Journal of neurology and psychiatry named after S. S. Korsakova. 2020; 120 (3 outp. 2): 60-65.
- Egorov E.A., Gvetadze A. A, Davydova N. G. Antioxidant drug in neuroprotective therapy for glaucoma // Bulletin of ophthalmology, No. 2, 2013, p. 67–69.
- Loskutov I.A., Andryukhina O.M., Kovrizhkina A.A. The use of Mexidol in therapy of primary open -angle glaucoma. Effective pharmacotherapy. 2022; 18 (11): 52–56.
- Duma S. N. The possibilities of antioxidant therapy for asthenia and cognitive deficiency in elderly patients with chronic brain ischemia // Therapeutic archive, No. 12, 2013, pp. 100–105.
Information is intended for medical and pharmaceutical workers. This information cannot serve as a replacement for a doctor’s consultation.
Source of photos and images Shutterstock.com